Based in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company. Our mission is to cure leading forms of blindness and transform the lives of millions of patients, by developing a platform of advanced therapies to treat ocular diseases. Our first candidate is for the treatment of corneal edema, and one of the first clinically validated cell therapies for corneal care. Healthy cells from a donor cornea are cultured in a novel, multi-step, proprietary and patented process. Cells from a single donor can be used to treat more than 100 recipient eyes. In clinical trials in Japan, patients have experienced significant and durable improvements in key measures of corneal health: visual acuity, corneal endothelial cell density and corneal thickness.
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia, a major global unmet medical need. Sydnexis manufactures pharmaceutical product for ophthalmic disorder or condition.
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.
Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections. Their delivery platforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers. Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more. The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.
Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
Surface Pharmaceuticals is an owner and operator of a pharmaceutical company intended to provide ophthalmology products. The company's medicines use topical formulations with the patented Klarity delivery vehicle, designed to protect and rehabilitate the ocular surface, enabling patients with dry eye disease to recover on time and properly.
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, and easy-to-use.
Tear Film Innovations (tearfilm.com) has developed the iLux® Dry Eye Treatment System, a breakthrough medical device for treating evaporative dry eye. Evaporative dry eye is the most prevalent form of dry eye and affects more than 330M people worldwide. The FDA-cleared, handheld iLux device enables an eye care professional to evaluate and treat dry eye patients in less than ten minutes.
Equinox is a developer of a medical technology in revolutionizing the treatment of glaucoma and other progressive eye diseases. It uses adjustable, non-surgical, a non-pharmacological system that utilizes the natural laws of physics to balance pressures in and around their eye, enabling doctors to understand glaucoma based on a deep exploration into the physics of the eye pressure. It was founded in 2014 and is headquartered in Newport Beach, California.
Tear Film Innovations (tearfilm.com) has developed the iLux® Dry Eye Treatment System, a breakthrough medical device for treating evaporative dry eye. Evaporative dry eye is the most prevalent form of dry eye and affects more than 330M people worldwide. The FDA-cleared, handheld iLux device enables an eye care professional to evaluate and treat dry eye patients in less than ten minutes.
Iantech has developed advanced micro-interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-interventional technique designed to deliver energy-free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgical technique. At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world
TearClear is a pharmaceutical company that specializes in providing a class platform of drugs that enables medication delivery to ultimately enhance patient safety and compliance by capturing preservatives before they reach the ocular surface. Founded in 2015, TearClear is headquartered in California, United States.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL®), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The LAL now features ActivShield™ technology, a revolutionary UV protection layer built into the lens.
CorneaGen innovates cornea care, from new medical devices and biologics to therapeutics and interventions. CorneaGen is a mission-driven company committed to transforming how corneal surgeons treat and care for the cornea. CorneaGen supports corneal surgeons and their patients with a spectrum of services, including the latest in innovative products, delivery of the highest quality tissue, surgeon education, and advocacy for patient access and reimbursement policies.
Iantech has developed advanced micro-interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-interventional technique designed to deliver energy-free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgical technique. At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world
Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.